Biotherapeutics company 4D pharma (Leeds) has announced progress on its development program for lead immuno-oncology single strain Live Biotherapeutic candidate MRx0518, an ongoing Phase I/II clinical trial in combination with immune checkpoint inhibitor (ICI) Keytruda(R) (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with advanced malignancies who have previously progressed on ICI therapy. Click to read more.
Relay Medical Corp.: Relay Medical Reports Glow LifeTech Secures Exclusive North American Rights to ArtemiC Following Successful COVID-19 Phase II Clinical Trial
Relay or the
Company ), a technology developer and innovator, and Glow LifeTech Ltd. (
Glow ), a private company in which Relay holds a significant equity interest, are pleased to report that Glow has executed an agreement with Swiss Pharmacan AG ( the agreement ) for exclusive North American and Carribean sales and distribution rights for ArtemiC , a natural health product based on Glow s MyCell Technology ( MyCell ) which recently reported successful results from a COVID-19 Phase II clinical trial (see Relay s release dated Jan 14, 2021).
Press release content from Business Wire. The AP news staff was not involved in its creation.
One Third of Medicare and Medicaid Beneficiaries Face Transportation Insecurity That Affects Access to Healthcare and Essential Medications
February 16, 2021 GMT
One Third of Medicare and Medicaid Beneficiaries Face Transportation Insecurity That Affects Access to Healthcare and Essential Medications (Graphic: Business Wire)
One Third of Medicare and Medicaid Beneficiaries Face Transportation Insecurity That Affects Access to Healthcare and Essential Medications (Graphic: Business Wire)
SAN MATEO, Calif. (BUSINESS WIRE) Feb 16, 2021
Continuing its commitment to healthcare equity, Evidation today announced the results of a national survey conducted in partnership with Lyft Healthcare to better understand transportation needs and insecurity among Medicare and Medicaid beneficiaries. The results suggest that transportation insecurity may magnify health disparities, and that healthcare in
Pfizer Inc. s Covid-19 mRNA vaccine got the final approval for emergency use on Sunday from health minister Norihisa Tamura, two days after a government committee gave the shot its seal of approval, paving the way for inoculations to start as early as Wednesday, The Japan Times reported.The